BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...a broader range of PAM (protospacer adjacent motif...
...Interleukin-2IL-18 – Interleukin-18SARM1- Sterile alpha and TIR motif...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...scientists detailed a similar concept in Cell Chemical Biology in December.TARGETSSARM1 – Sterile alpha and TIR motif...
...in St. Louis Broad Institute of MIT and Harvard Novartis Institutes for BioMedical Research Sterile alpha and TIR motif...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...Transmembrane protein 120A TRIM25 - Tripartite motif...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...COVID-19 mAbs bind to the receptor binding motif...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...in Queensland’s CEPI-funded Phase I trial. v451 uses Queensland’s “molecular clamp,” an 80-amino acid trimerization motif...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

...β (IFNB1); interferon-stimulated gene 15 (ISG15); interleukin-6 (IL-6); tumor necrosis factor α (TNFα); chemokine CXC motif...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...identified enzymes that can have protospacer adjacent motif...
BioCentury | Nov 12, 2020
Management Tracks

ObsEva, Korro bring in new CEOs; plus Cerebral, Spartan, Apnimed and Micronoma

...as COO and co-founder Greg Poore as chief analytic officer. Adams was VP of R&D at Active Motif...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...member 5A (WNT5A); collagen type II alpha 1 chain (COL2A1); ADAM metallopeptidase with thrombospondin type 1 motif...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...approved Emgality for migraine prevention in 2018. TARGETSCGRP – calcitonin gene-related peptide SARM1 – sterile alpha and TIR motif...
Items per page:
1 - 10 of 613
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...a broader range of PAM (protospacer adjacent motif...
...Interleukin-2IL-18 – Interleukin-18SARM1- Sterile alpha and TIR motif...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...scientists detailed a similar concept in Cell Chemical Biology in December.TARGETSSARM1 – Sterile alpha and TIR motif...
...in St. Louis Broad Institute of MIT and Harvard Novartis Institutes for BioMedical Research Sterile alpha and TIR motif...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...Transmembrane protein 120A TRIM25 - Tripartite motif...
BioCentury | Dec 19, 2020
Product Development

Why Vir, Brii believe their mAbs may succeed where others have failed

...COVID-19 mAbs bind to the receptor binding motif...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...in Queensland’s CEPI-funded Phase I trial. v451 uses Queensland’s “molecular clamp,” an 80-amino acid trimerization motif...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

...β (IFNB1); interferon-stimulated gene 15 (ISG15); interleukin-6 (IL-6); tumor necrosis factor α (TNFα); chemokine CXC motif...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...identified enzymes that can have protospacer adjacent motif...
BioCentury | Nov 12, 2020
Management Tracks

ObsEva, Korro bring in new CEOs; plus Cerebral, Spartan, Apnimed and Micronoma

...as COO and co-founder Greg Poore as chief analytic officer. Adams was VP of R&D at Active Motif...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...member 5A (WNT5A); collagen type II alpha 1 chain (COL2A1); ADAM metallopeptidase with thrombospondin type 1 motif...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...approved Emgality for migraine prevention in 2018. TARGETSCGRP – calcitonin gene-related peptide SARM1 – sterile alpha and TIR motif...
Items per page:
1 - 10 of 613